Hutchens & Kramer Investment Management Group’s AbbVie ABBV Stock Holding History

Hutchens & Kramer Investment Management Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$264K	Buy	1,008 +23	+2%	+$5.9K	0.08%	127
2026 Q2	$248K	Buy	985 +6	+0.6%	+$1.29K	0.07%	139
2026 Q1	$213K	Sell	979 -1,029	-51%	-$228K	0.07%	141
2025 Q4	$459K	Sell	2,008 -2	-0.1%	-$456	0.16%	86
2025 Q3	$465K	Buy	2,010 +38	+2%	+$7.74K	0.18%	82
2025 Q2	$375K	Sell	1,972 -67	-3%	-$12.5K	0.17%	90
2025 Q1	$427K	Sell	2,039 -434	-18%	-$84.4K	0.24%	76
2024 Q4	$439K	Buy	2,473 +524	+27%	+$96.3K	0.24%	76
2024 Q3	$384K	Buy	1,949 +126	+7%	+$23.5K	0.21%	85
2024 Q2	$311K	Sell	1,823 -2	-0.1%	-$331	0.17%	99
2024 Q1	$330K	Buy	1,825 +73	+4%	+$12.6K	0.2%	88
2023 Q4	$272K	Buy	+1,752	New	+$255K	0.19%	91

Other funds holding ABBV

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Hutchens & Kramer Investment Management Group's ABBV Position: Q3 2026 in Review

Hutchens & Kramer Investment Management Group increased its AbbVie (ABBV) stake by 2.3% in Q3 2026, buying an estimated $5.9K and bringing the position to 1,008 shares worth $264K. The position accounts for 0.08% of the portfolio, ranked #127.

Hutchens & Kramer Investment Management Group first reported a position in ABBV in Q4 2023 and has held it in 12 quarters since. The position peaked at $465K in Q3 2025. 766 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Hutchens & Kramer Investment Management Group held 1,008 shares of AbbVie worth $264K as of Q3 2026.
Hutchens & Kramer Investment Management Group bought 23 AbbVie shares in Q3 2026, an estimated $5.9K.
AbbVie made up 0.08% of Hutchens & Kramer Investment Management Group's portfolio in Q3 2026, its #127 holding.
Hutchens & Kramer Investment Management Group first reported a position in AbbVie in Q4 2023 and has held it in 12 quarters since.
Hutchens & Kramer Investment Management Group's AbbVie position peaked at $465K in Q3 2025.
766 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Hutchens & Kramer Investment Management Group's 13F filing for Q3 2026, filed 16 Oct 2026.